JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.33 -3.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.31

Max

1.44

Belangrijke statistieken
By Trading Economics
Inkomsten	-103K -6.6M
Werknemers	42

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+171.74% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	19M 91M
Vorige openingsprijs	4.95
Vorige sluitingsprijs	1.33

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 apr 2026, 23:33 UTC

Winsten

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 apr 2026, 22:40 UTC

Winsten

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 apr 2026, 22:10 UTC

Acquisities, Fusies, Overnames

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:11 UTC

Winsten

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 apr 2026, 21:01 UTC

Winsten

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 apr 2026, 23:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 apr 2026, 23:46 UTC

Marktinformatie

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 apr 2026, 23:34 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 apr 2026, 23:16 UTC

Winsten

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 apr 2026, 23:15 UTC

Winsten

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 apr 2026, 22:54 UTC

Winsten

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 apr 2026, 22:54 UTC

Winsten

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 apr 2026, 22:52 UTC

Winsten

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 apr 2026, 22:51 UTC

Winsten

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 apr 2026, 22:31 UTC

Winsten

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 apr 2026, 22:31 UTC

Winsten

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 apr 2026, 22:30 UTC

Winsten

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 apr 2026, 22:30 UTC

Winsten

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 apr 2026, 22:29 UTC

Winsten

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 apr 2026, 22:28 UTC

Winsten

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 apr 2026, 22:28 UTC

Winsten

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 apr 2026, 22:27 UTC

Winsten

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 apr 2026, 22:06 UTC

Marktinformatie

Winsten

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 apr 2026, 21:55 UTC

Acquisities, Fusies, Overnames

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:47 UTC

Winsten

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:37 UTC

Winsten

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 apr 2026, 21:34 UTC

Winsten

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 apr 2026, 21:29 UTC

Winsten

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:20 UTC

Marktinformatie

Winsten

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

171.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.75 USD 171.74%

Hoogste 4 USD

Laagste 3.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.